Isolation of rabbit bone marrow mesenchymal stem cells using density gradient centrifugation and adherence screening methods

Journal of Clinical Rehabilitative Tissue Engineering Research

Volumn 13, Issue 6, 2009, Pages 1181-1184

  Zhang, Cai Long ^a   Xia, Chang Suo ^a   Jiang, Zheng Yao ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; HERMES ANTIGEN; THY 1 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; DENSITY GRADIENT CENTRIFUGATION; FEMALE; HEMATOPOIETIC STEM CELL; IMMUNOCYTOCHEMISTRY; MESENCHYMAL STEM CELL; NONHUMAN; OBSERVATIONAL STUDY; RABBIT; REPRODUCIBILITY; STRUCTURE ACTIVITY RELATION; TISSUE ENGINEERING; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 62549105270     PISSN: 16738225     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Hong JH, Yaffe MB. TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle. 2006;5(2):176-179.
2. Lin HT, Tarng YW, Chen YC, et al. Using human plasma supplemented medium to cultivate human bone marrow-derived mesenchymal stem cell and evaluation of its multiple-lineage potential. Transplantation Proc. 2005;37(10):4504-4505.
3. The Ministry of Science and Technology of the People's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.
4. Popat U, Heslop HE, Durett A, et al. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant. 2006;37(6):547-552.
5. Platzbecker U, Thiede C, Fussel M, et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia. 2006;20(4):707-714.
6. Berry MF, Engler AJ, Woo YJ, et al. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol. 2006;290(6): H2196-2203.
7. Knippenberg M, Helder MN, Doulabi BZ, et al. Adipose tissue-derived mesenchymal stem cells acquire bone cell-like responsiveness to fluid shear stress on osteogenic stimulation. Tissue Eng. 2005;11(11-12):1780-1788.
8. Xu SQ, Xu YG. Recent progress of BMSCs acting as seeding cell for tissue engineered cartilage. Zhongguo Xiufu Chongjian Waike Zazhi. 2008;28(2):163-166.
9. Hu W, Xiang Z, Zhang XL, et al. Preliminary study of BMSCs seeded into collagen glycosaminoglycan matrices induced toward cartilage. Zhongguo Xiufu Chongjian Waike Zazhi. 2008;28(2): 153-156.
10. Wulf GG, Jackson KA, Goodell MA. Somatic stem cell plasticity: current evidence and emerging concepts. Exp Hematol. 2001;29(12):1361-1370.
11. Barry FP. Mesenchymal stem cell therapy in joint disease. Novartis Found Symp. 2003;249:86-96.
12. Kadiyala S, Young RG, Thiede MA, et al. Culture expanded canine mesenchymal stem cells possess osteochondrogenic potential in vivo and in vitro. Cell Transplant. 1997;6(2):125-134.